BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32631090)

  • 21. Hypoxia-inducible factor-1 α regulates prion protein expression to protect against neuron cell damage.
    Jeong JK; Seo JS; Moon MH; Lee YJ; Seol JW; Park SY
    Neurobiol Aging; 2012 May; 33(5):1006.e1-10. PubMed ID: 22036844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
    Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
    Viruses; 2019 May; 11(5):. PubMed ID: 31083283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prions, prionoids and protein misfolding disorders.
    Scheckel C; Aguzzi A
    Nat Rev Genet; 2018 Jul; 19(7):405-418. PubMed ID: 29713012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanisms of prion transmission].
    Sakaguchi S
    Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid cell-surface prion protein conversion revealed using a novel cell system.
    Goold R; Rabbanian S; Sutton L; Andre R; Arora P; Moonga J; Clarke AR; Schiavo G; Jat P; Collinge J; Tabrizi SJ
    Nat Commun; 2011; 2():281. PubMed ID: 21505437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prion proteins: a biological role beyond prion diseases.
    Hu W; Rosenberg RN; Stüve O
    Acta Neurol Scand; 2007 Aug; 116(2):75-82. PubMed ID: 17661791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prion protein-Semisynthetic prion protein (PrP) variants with posttranslational modifications.
    Hackl S; Becker CFW
    J Pept Sci; 2019 Oct; 25(10):e3216. PubMed ID: 31713950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cellular prion protein (PrP(C)): its physiological function and role in disease.
    Westergard L; Christensen HM; Harris DA
    Biochim Biophys Acta; 2007 Jun; 1772(6):629-44. PubMed ID: 17451912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
    Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
    J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
    Gilch S; Nunziante M; Ertmer A; Schätzl HM
    Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving views in prion glycosylation: functional and pathological implications.
    Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
    Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of endoproteolytic α-cleavage and shedding of the prion protein in neurodegeneration.
    Altmeppen HC; Prox J; Puig B; Dohler F; Falker C; Krasemann S; Glatzel M
    FEBS J; 2013 Sep; 280(18):4338-47. PubMed ID: 23413979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.
    Liemann S; Glockshuber R
    Biochemistry; 1999 Mar; 38(11):3258-67. PubMed ID: 10079068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prion's elusive reason for being.
    Aguzzi A; Baumann F; Bremer J
    Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurodevelopmental expression and localization of the cellular prion protein in the central nervous system of the mouse.
    Benvegnù S; Poggiolini I; Legname G
    J Comp Neurol; 2010 Jun; 518(11):1879-91. PubMed ID: 20394048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting prion proteins in neurodegenerative disease.
    Gilch S; Krammer C; Schätzl HM
    Expert Opin Biol Ther; 2008 Jul; 8(7):923-40. PubMed ID: 18549323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prion protein aggregation and fibrillogenesis in vitro.
    Stöhr J
    Subcell Biochem; 2012; 65():91-108. PubMed ID: 23225001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strain specificity and drug resistance in anti-prion therapy.
    Miller-Vedam L; Ghaemmaghami S
    Curr Top Med Chem; 2013; 13(19):2397-406. PubMed ID: 24059341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small is not beautiful: antagonizing functions for the prion protein PrP(C) and its homologue Dpl.
    Behrens A; Aguzzi A
    Trends Neurosci; 2002 Mar; 25(3):150-4. PubMed ID: 11852147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The metabolism of glycosaminoglycans is impaired in prion diseases.
    Mayer-Sonnenfeld T; Zeigler M; Halimi M; Dayan Y; Herzog C; Lasmezas CI; Gabizon R
    Neurobiol Dis; 2005 Dec; 20(3):738-43. PubMed ID: 15951190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.